Novo Holdings Joins TA to Reinvest in Bio composites for Pharmaceutics Growth

Bio composites secures reinvestment from Novo Holdings and TA, aiming to expand globally and enhance innovation.

As part of the deal, Biocomposites' management and new investor Novo Holdings will reinvest in the company alongside TA, which has been the company's largest shareholder since 2017. As a result of the deal, Novo Holdings and TA share control over Biocomposites.

With more than 30 years of experience, Biocomposites' cutting-edge solutions are utilized in over a million treatments every year in a variety of specializations, such as sports injuries, orthopaedics, trauma, musculoskeletal infections, and foot and ankle issues.

Bio composites have seen tremendous progress since collaborating with TA in 2017; this includes a threefold rise in sales, successful global expansion, and ongoing product diversification.  Additionally, the company has made two significant acquisitions that have expanded its global reach and allowed it to enter related therapeutic areas and indications. 

With Novo Holdings' new investment and TA's continued backing, Biocomposites hopes to build on this momentum by expanding its global presence and developing its pipeline of cutting-edge technologies to provide transformative solutions on a large scale.

Henrik Kjær Hansen, a senior partner at Novo Holdings, expressed excitement about the partnership with Biocomposites and TA, marking a significant new chapter for the company. He highlighted that Biocomposites' innovative infection management solutions align well with Novo Holdings' broader life sciences investment portfolio, emphasizing the company's strong growth potential. With their expertise in life sciences and a vast global network, Novo Holdings is eager to support Biocomposites in expanding internationally, fostering innovation, and advancing infection management solutions to improve patient outcomes globally.

Michael Harris, CEO of Biocomposites, reflected on the long-term partnership with TA and his enthusiasm about the future collaboration with both TA and Novo Holdings. He stated that this asset validates the company's accomplishments and future growth prospects.

With the combined expertise and support from these leading global healthcare investors, Biocomposites is well-positioned to enhance its commitment to delivering innovative infection management products to a wider audience, ultimately transforming patient outcomes.